Zafgen Inc (ZFGN) : Foresite Capital Management Ii reduced its stake in Zafgen Inc by 46.56% during the most recent quarter end. The investment management company now holds a total of 760,046 shares of Zafgen Inc which is valued at $2,454,949 after selling 662,227 shares in Zafgen Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Zafgen Inc makes up approximately 1.56% of Foresite Capital Management Ii’s portfolio.
Other Hedge Funds, Including , Spark Investment Management added ZFGN to its portfolio by purchasing 200,300 company shares during the most recent quarter which is valued at $646,969. Zafgen Inc makes up approx 0.06% of Spark Investment Management’s portfolio. Tfs Capital added ZFGN to its portfolio by purchasing 16,029 company shares during the most recent quarter which is valued at $51,774. Zafgen Inc makes up approx 0.01% of Tfs Capital’s portfolio. Princeton Alpha Management Lp sold out all of its stake in ZFGN during the most recent quarter. The investment firm sold 27,221 shares of ZFGN which is valued $87,652. Dekabank Deutsche Girozentrale sold out all of its stake in ZFGN during the most recent quarter. The investment firm sold 12,000 shares of ZFGN which is valued $38,640. Financial Architects Inc added ZFGN to its portfolio by purchasing 1,600 company shares during the most recent quarter which is valued at $4,960.
Zafgen Inc closed down -0.05 points or -1.64% at $3 with 3,51,225 shares getting traded on Monday. Post opening the session at $3.07, the shares hit an intraday low of $2.95 and an intraday high of $3.085 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Zafgen Inc reported $-0.65 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.72.During the same quarter in the previous year, the company posted $-0.53 EPS.
Many Wall Street Analysts have commented on Zafgen Inc. Shares were Downgraded by FBR Capital on Jul 20, 2016 to ” Mkt Perform” and Lowered the Price Target to $ 5 from a previous price target of $20 .
Zafgen Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications including severe obesity in two rare diseases Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO) including craniopharyngioma-associated obesity and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO and is in Phase IIb stage of development for severe obesity in the general population. The Company’s other product candidate ZGN-839 is in pre-clinical development stage. The Company is also evaluating the additional MetAP2 inhibitors beyond Beloranib as potential development candidates for the treatment of severe obesity.